Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT).

AIMS Despite widely available risk stratification tools, safe and effective anticoagulant options, and guideline recommendations, anticoagulation for stroke prevention in atrial fibrillation (AF) is underprescribed. We created and evaluated an alert-based computerized decision support (CDS) strategy to increase anticoagulation prescription in hospitalized AF patients at high risk for stroke. METHODS AND RESULTS We enrolled 458 patients (CHA2DS2-VASc score ≥1) with AF who were not prescribed anticoagulant therapy and were hospitalized at Brigham and Women's Hospital. Patients were randomly allocated, according to Attending Physician of record, to intervention (alert-based CDS) vs. control (no notification). The primary efficacy outcome was the frequency of anticoagulant prescription. The CDS tool assigned 248 patients to the alert group and 210 to the control group. Patients in the alert group were more likely to be prescribed anticoagulation during the hospitalization (25.8% vs. 9.5%, P < 0.0001), at discharge (23.8% vs. 12.9%, P = 0.003), and at 90 days (27.7% vs. 17.1%, P = 0.007). The alert reduced the odds of a composite outcome of death, myocardial infarction (MI), cerebrovascular event, and systemic embolic event at 90 days [11.3% vs. 21.9%, P = 0.002; odds ratio (OR) 0.45; 95% confidence interval (CI) 0.27-0.76]. The alert reduced the odds of MI at 90 days by 87% (1.2% vs. 8.6%, P = 0.0002; OR 0.13; 95% CI 0.04-0.45) and cerebrovascular events or systemic embolism at 90 days by 88% (0% vs. 2.4%, P = 0.02; OR 0.12; 95% CI 0.0-0.91). CONCLUSION An alert-based CDS strategy increased anticoagulation in high-risk hospitalized AF patients and reduced major adverse cardiovascular events, including MI and stroke. CLINICALTRIALS.GOV IDENTIFIER NCT02339493.

[1]  S. Goldhaber,et al.  Fine-tuning the decision to initiate anticoagulation in atrial fibrillation by accounting for age and cardiovascular comorbidities. , 2019, European heart journal.

[2]  Pamela J. McCabe,et al.  Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation Is Achievable: First Results From Get With The Guidelines–Atrial Fibrillation (GWTG-AFIB) , 2019, Circulation.

[3]  Michael A. Rodriguez,et al.  Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry , 2019, Journal of the American Heart Association.

[4]  D. Fitzmaurice,et al.  Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation: Results From the GARFIELD-AF Registry , 2019, Circulation.

[5]  G. Guyatt,et al.  Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial , 2018, The Lancet.

[6]  D. Fitzmaurice,et al.  Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation , 2018, PloS one.

[7]  S. Goldhaber,et al.  Anticoagulation and Mortality Rates among Hospitalized Patients with Atrial Fibrillation , 2018, TH Open.

[8]  Ameen Abu-Hanna,et al.  The Effect of a Clinical Decision Support System on Improving Adherence to Guideline in the Treatment of Atrial Fibrillation: An Interrupted Time Series Study , 2018, Journal of Medical Systems.

[9]  G. Fonarow,et al.  International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD‐AF, ORBIT‐AF I, and ORBIT‐AF II registries , 2017, American heart journal.

[10]  Mircea Cinteza,et al.  A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial , 2017, The Lancet.

[11]  D. Singer,et al.  Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. , 2017, The American journal of medicine.

[12]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[13]  P. Magin,et al.  Optimizing Stroke Prevention in Patients With Atrial Fibrillation: A Cluster-Randomized Controlled Trial of a Computerized Antithrombotic Risk Assessment Tool in Australian General Practice, 2012–2013 , 2016, Preventing chronic disease.

[14]  D. Fitzmaurice,et al.  Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF , 2016, European heart journal.

[15]  Farzaneh A. Sorond,et al.  North American Thrombosis Forum, AF Action Initiative Consensus Document. , 2016, The American journal of medicine.

[16]  S. Goldhaber,et al.  Randomized trial of physician alerts for thromboprophylaxis after discharge. , 2013, The American journal of medicine.

[17]  Jeroen J. Bax,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.

[18]  Isabelle Boutron,et al.  Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors , 2012, BMJ : British Medical Journal.

[19]  Douglas Weaver,et al.  Third universal definition of myocardial infarction. , 2012, Circulation.

[20]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[21]  Marilyn D Paterno,et al.  Physician Alerts to Prevent Symptomatic Venous Thromboembolism in Hospitalized Patients , 2009, Circulation.

[22]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.